Health Care Sector Equities Technical Commentary -- Research on AbbVie, GlaxoSmithKline, AstraZeneca and Novartis Editor Note: For more information about this release, please scroll to bottom
LONDON, March 21, 2014 /PRNewswire/ --
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average advanced 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), GlaxoSmithKline PLC (NYSE: GSK), AstraZeneca PLC (NYSE: AZN) and Novartis AG (NYSE: NVS). Free technical research on ABBV, GSK, AZN and NVS can be downloaded upon signing up at:
AbbVie Inc.'s stock gained 1.07% on Thursday, closing at $53.68 after oscillating between $52.52 and $53.80. A total of 6.92 million shares were traded, which is above the three months average volume of 6.39 million. The company's shares have advanced 3.27% in the previous three trading sessions, 3.51% in the last one month and 1.65% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages. AbbVie Inc.'s 50-day moving average of $50.25 is above the 200-day moving average of $47.33. Furthermore, the stock is trading at a PE ratio of 18.43 and at an Relative Strength Index (RSI) of 66.09. Sign up today to read free research on ABBV at:
Shares in GlaxoSmithKline PLC witnessed a trading volume of 2.29 million shares, as compared with a three months average volume of 2.30 million shares. The stock ended the day at $54.02, down 1.26% and at an intraday trading range of $53.69 and $54.07 during the session. Shares in GlaxoSmithKline PLC have lost 3.91% in the last one month, while the same has gained 5.14% in the previous three months and 1.18% on YTD basis. The stock is trading above its 200-day moving average. GlaxoSmithKline PLC's 50-day moving average of $54.23 is above the 200-day moving average of $52.28. Additionally, shares of the company are trading at an RSI of 47.69. Sign up today to read free research on GSK at:
On Thursday, shares in AstraZeneca PLC declined 1.37%, finishing the session at $64.85. The stock recorded a trading volume of 1.52 million shares as compared to a three months average volume of 2.43 million shares. The stock fluctuated between $64.71 and $65.16 during the session and has fallen by 2.66% in the last one month. Shares in AstraZeneca PLC have rallied 11.20% in the previous three months and 9.23% on YTD basis. The stock is trading above its 200-day moving average. AstraZeneca PLC's 50-day moving average of $64.93 is above the 200-day moving average of $55.30. Moreover, the stock is trading at an RSI of 48.29. Sign up today to read free research on AZN at:
Novartis AG's stock recorded a trading volume of 1.12 million shares, as compared with a three months average volume of 1.80 million shares. The stock ended Thursday's session at $81.31, up 0.12%, and at an intraday trading range of $80.64 and $81.46. Shares in Novartis AG have gained 3.82% in the previous three months and 1.16% on YTD basis. The stock is trading above its 200-day moving average. Novartis AG's 50-day moving average of $81.36 is above the 200-day moving average of $76.75. Further, the stock is trading at an RSI of 45.03. Sign up today to read free research on NVS at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.